Advertisement

Transcatheter Aortic Valve Therapies

  • Mohanad HamandiEmail author
  • Michael J. Mack
Chapter
  • 9 Downloads

Abstract

Since the introduction of transcatheter aortic valve implantation (TAVI) in 2002 by Cribier, the management of patients with severe aortic stenosis has undergone substantial transformation. TAVI has emerged as an effective treatment option in patients with severe aortic stenosis in large part due to a robust evidence base generated by a series of randomized controlled trials. It is now the preferred treatment modality in intermediate-, high-, and prohibitive surgical risk patients. Randomized trials of low surgical risk patients have completed enrollment and may significantly increase the candidacy of TAVI patients when the results become available in early 2019. Despite the significant improvement in technology, there are challenging issues that need to be optimized such as pacemaker rates, stroke, valve durability and thrombosis. This chapter provides an overview of the evidence base, current technology, guidelines and challenging issues related to TAVI.

Keywords

Balloon aortic valvuloplasty PARTNER 1A trial PARTNER 1B trial PARTNER 2A trial Transcatheter aortic valve implantation Transcatheter aortic valve therapies 

References

  1. 1.
    Cribier A, Savin T, Saoudi N, Rocha P, Berland J, Letac B. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet. 1986;1:63–7.CrossRefGoogle Scholar
  2. 2.
    Letac B, Cribier A, Koning R, Bellefleur JP. Results of percutaneous transluminal valvuloplasty in 218 adults with valvular aortic stenosis. Am J Cardiol. 1988;62:598–605.CrossRefGoogle Scholar
  3. 3.
    Andersen HR, Knudsen LL, Hasenkam JM. Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs. Eur Heart J. 1992;13:704–8.CrossRefGoogle Scholar
  4. 4.
    Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403–5.CrossRefGoogle Scholar
  5. 5.
    Cribier AG. The Odyssey of TAVR from concept to clinical reality. Tex Heart Inst J. 2014;41:125–30.CrossRefGoogle Scholar
  6. 6.
    Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106:3006–8.CrossRefGoogle Scholar
  7. 7.
    Holmes DR Jr, Rich JB, Zoghbi WA, Mack MJ. The heart team of cardiovascular care. J Am Coll Cardiol. 2013;61:903–7.CrossRefGoogle Scholar
  8. 8.
    Beohar N, Whisenant B, Kirtane AJ, et al. The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons score in the Placement of Aortic Transcatheter Valves trial. J Thorac Cardiovasc Surg. 2014;148:2830–7.e1.CrossRefGoogle Scholar
  9. 9.
    Ben-Dor I, Gaglia MA, Jr., Barbash IM, et al. Comparison between Society of Thoracic Surgeons score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation. Cardiovasc Revasc Med. 2011;12:345–9.CrossRefGoogle Scholar
  10. 10.
    Edwards FH, Cohen DJ, O’Brien SM, et al. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol. 2016;1:46–52.CrossRefGoogle Scholar
  11. 11.
    Chamandi C, Puri R, Rodriguez-Gabella T, Rodes-Cabau J. Latest-generation transcatheter aortic valve replacement devices and procedures. Can J Cardiol. 2017;33:1082–90.CrossRefGoogle Scholar
  12. 12.
    De Torres-Alba F, Kaleschke G, Diller GP, et al. Changes in the pacemaker rate after transition from Edwards SAPIEN XT to SAPIEN 3 transcatheter aortic valve implantation: the critical role of valve implantation height. JACC Cardiovasc Interv. 2016;9:805–13.CrossRefGoogle Scholar
  13. 13.
    Todaro D, Barbanti M. Current TAVR devices technical characteristics and evidence to date for FDA- and CE Mark-approved valves 2017 [updated April 2017]. Available from: https://citoday.com/pdfs/cit0317_F5_Barbanti.pdf.
  14. 14.
    Sorajja P, Kodali S, Reardon MJ, et al. Outcomes for the commercial use of self-expanding prostheses in transcatheter aortic valve replacement: a report from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2017;10:2090–8.CrossRefGoogle Scholar
  15. 15.
    Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRefGoogle Scholar
  16. 16.
    Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefGoogle Scholar
  17. 17.
    Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–81.CrossRefGoogle Scholar
  18. 18.
    Young MN, Singh V, Sakhuja R. A review of alternative access for transcatheter aortic valve replacement. Curr Treat Options Cardiovasc Med. 2018;20:62.CrossRefGoogle Scholar
  19. 19.
    Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.CrossRefGoogle Scholar
  20. 20.
    Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.CrossRefGoogle Scholar
  21. 21.
    Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31.CrossRefGoogle Scholar
  22. 22.
    Thyregod HG, Steinbruchel DA, Ihlemann N, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65:2184–94.CrossRefGoogle Scholar
  23. 23.
    Waksman R, Rogers T, Torguson R, Gordon P, Ehsan A, Wilson SR, et al. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol. 2018;72:2095–105.CrossRefGoogle Scholar
  24. 24.
    Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.CrossRefGoogle Scholar
  25. 25.
    Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar
  26. 26.
    Urena M, Rodes-Cabau J. Permanent pacemaker implantation following transcatheter aortic valve replacement: still a concern? JACC Cardiovasc Interv. 2015;8(1 Pt A):70–3.CrossRefGoogle Scholar
  27. 27.
    Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1Pt A):60–9.CrossRefGoogle Scholar
  28. 28.
    Latsios G, Gerckens U, Buellesfeld L, et al. “Device landing zone” calcification, assessed by MSCT, as a predictive factor for pacemaker implantation after TAVI. Catheter Cardiovasc Interv. 2010;76:431–9.CrossRefGoogle Scholar
  29. 29.
    Lansky AJ, Brown D, Pena C, et al. Neurologic complications of unprotected transcatheter aortic valve implantation (from the Neuro-TAVI Trial). Am J Cardiol. 2016;118:1519–26.CrossRefGoogle Scholar
  30. 30.
    Van Mieghem NM, van Gils L, Ahmad H, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. EuroIntervention. 2016;12:499–507.CrossRefGoogle Scholar
  31. 31.
    Haussig S, Mangner N, Dwyer MG, et al. Effect of a cerebral protection device on brain lesions following transcatheter aortic valve implantation in patients with severe aortic stenosis: the CLEAN-TAVI randomized clinical trial. JAMA. 2016;316:592–601.CrossRefGoogle Scholar
  32. 32.
    Kapadia SR, Kodali S, Makkar R, et al. Protection against cerebral embolism during transcatheter aortic valve replacement. J Am Coll Cardiol. 2017;69:367–77.CrossRefGoogle Scholar
  33. 33.
    Lansky AJ, Schofer J, Tchetche D, et al. A prospective randomized evaluation of the TriGuard HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. Eur Heart J. 2015;36:2070–8.CrossRefGoogle Scholar
  34. 34.
    Hansson NC, Grove EL, Andersen HR, Leipsic J, Mathiassen ON, Jensen JM, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–69.CrossRefGoogle Scholar
  35. 35.
    Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:2440–92.CrossRefGoogle Scholar
  36. 36.
    Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772–6.CrossRefGoogle Scholar
  37. 37.
    Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624–7.CrossRefGoogle Scholar
  38. 38.
    Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial. JACC Cardiovasc Interv. 2017;10:1357–65.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Baylor Scott and White-The Heart HospitalPlanoUSA

Personalised recommendations